Clinical Trial Update: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating almonertinib as first-line treatment for EGFR-positive pulmonary adenosquamous carcinoma or combined adenocarcinoma and squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Adenosquamous Carcinoma

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Pulmonary Adenosquamous Carcinoma | Phase 2 | Status: UNKNOWN